New biologics and long-acting agents (WAYPOINT & ANCHOR) reshape CRSwNP landscape
Key Questions
What new biologics are reshaping the CRSwNP treatment landscape?
Tezepelumab (anti-TSLP, Tezspire) and depemokimab (anti-IL-5), from the WAYPOINT and ANCHOR studies, show SNOT-22 score improvements and reduced need for surgery or steroids in CRSwNP patients. Tezepelumab sales surged 495% to 340 million roubles. These complement dupilumab, especially with 48% asthma comorbidity overlap.
What is driving the growth in the asthma and COPD drug market?
The market grew 6.2% due to increasing demand for biologics. This shift highlights the rising adoption of targeted therapies like tezepelumab and depemokimab. No specific data on AERD is available yet.
What should be monitored for personalized CRSwNP care?
Track biomarkers such as FeNO, eosinophils, and registries, along with GINA 2025/2026 guidelines for access and personalization. FeNO testing helps assess symptoms like coughing and wheezing in related conditions. This supports tailored use of biologics amid high asthma comorbidity.
Tezepelumab (anti-TSLP, Tezspire sales +495% to 340M roubles) and depemokimab (anti-IL-5) show SNOT-22 gains, less surgery/steroids in CRSwNP, market growth 6.2% on biologics demand. No AERD data yet; complements dupilumab (PI notes 48% asthma comorbidity overlap)—track biomarkers/registries/FeNO/eosinophils/GINA 2025/2026 for personalized care/access.